Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Myocarditis I: Introduction

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...

Myasthenia Gravis ll: Pathophysiology

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...

Disorders of the Skeletal Muscle

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Neurology·2026

Same author

Optimizing rare neurological disease trials: Bayesian frameworks and hierarchical models for improved efficiency in clinical trial design.

Journal of biopharmaceutical statistics·2026

Same author

A Phase 3 Trial of Brepocitinib in Dermatomyositis.

The New England journal of medicine·2026

Same author

Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe disease.

Therapeutic advances in rare disease·2026

Same author

Shared governance of international myositis networks.

Clinical and experimental rheumatology·2026

Same author

Dynamics of Nerve Conduction Studies in Patients With Guillain-Barré Syndrome.

Muscle & nerve·2026

Search research articles

Related Experiment Video

Updated: Apr 26, 2026

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

Inclusion body myositis.

Mazen M Dimachkie¹, Richard J Barohn²

¹Neuromuscular Section, Neurophysiology Division, Department of Neurology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Mail Stop 2012, Kansas City, KS 66160, USA.

Neurologic Clinics

|July 20, 2014

Summary

This summary is machine-generated.

Inclusion body myositis (IBM) is a common idiopathic inflammatory myopathy (IIM) in those over 50. Research is evolving, focusing on its degenerative aspects and new clinical trials.

Keywords:

Diagnosis Idiopathic inflammatory myopathies Inclusion body myositis Pathology Pathophysiology Polymyositis Prognosis Treatment

More Related Videos

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

Minimally Invasive Muscle Embedding MIME - A Novel Experimental Technique to Facilitate Donor-Cell-Mediated Myogenesis

Minimally Invasive Muscle Embedding MIME - A Novel Experimental Technique to Facilitate Donor-Cell-Mediated Myogenesis

Published on: August 24, 2017

Related Experiment Videos

Last Updated: Apr 26, 2026

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

Minimally Invasive Muscle Embedding MIME - A Novel Experimental Technique to Facilitate Donor-Cell-Mediated Myogenesis

Minimally Invasive Muscle Embedding MIME - A Novel Experimental Technique to Facilitate Donor-Cell-Mediated Myogenesis

Published on: August 24, 2017

Area of Science:

Neurology
Immunology
Rare Diseases

Background:

Idiopathic inflammatory myopathies (IIMs) are rare, heterogeneous disorders.
Inclusion body myositis (IBM) is the most frequent IIM in individuals over 50.
IBM shares features with other IIMs like dermatomyositis and polymyositis.

Purpose of the Study:

To review the historical progression of knowledge regarding IBM.
To highlight recent advancements in understanding IBM.
To discuss current and upcoming clinical trials for IBM.

Main Methods:

Review of existing literature on IBM.
Analysis of histopathological findings in IBM.
Examination of clinical trial data and progress.

Main Results:

Muscle biopsy in IBM reveals inflammatory infiltrates and protein deposits.
Rimmed vacuoles are a characteristic histopathological feature of IBM.
IBM likely possesses a significant degenerative component.

Conclusions:

IBM represents a complex IIM with both inflammatory and degenerative processes.
Ongoing research and clinical trials aim to improve diagnosis and treatment for IBM.
Further understanding of IBM's pathogenesis is crucial for therapeutic development.